JP7137563B2 - がん治療用の抗Ｓｉｇｌｅｃ－７抗体 - Google Patents

がん治療用の抗Ｓｉｇｌｅｃ－７抗体 Download PDF

Info

Publication number
JP7137563B2
JP7137563B2 JP2019527783A JP2019527783A JP7137563B2 JP 7137563 B2 JP7137563 B2 JP 7137563B2 JP 2019527783 A JP2019527783 A JP 2019527783A JP 2019527783 A JP2019527783 A JP 2019527783A JP 7137563 B2 JP7137563 B2 JP 7137563B2
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
siglec
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019527783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526622A5 (enExample
JP2019526622A (ja
Inventor
ベビントン クリストファー
コーバー ウター
トマセビク ネナド
エル バデル スージー
ラーセン ケネス
Original Assignee
アラコス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラコス，インコーポレイティド filed Critical アラコス，インコーポレイティド
Publication of JP2019526622A publication Critical patent/JP2019526622A/ja
Publication of JP2019526622A5 publication Critical patent/JP2019526622A5/ja
Application granted granted Critical
Publication of JP7137563B2 publication Critical patent/JP7137563B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019527783A 2016-08-05 2017-08-04 がん治療用の抗Ｓｉｇｌｅｃ－７抗体 Active JP7137563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662371680P 2016-08-05 2016-08-05
US62/371,680 2016-08-05
PCT/US2017/045641 WO2018027203A1 (en) 2016-08-05 2017-08-04 Anti-siglec-7 antibodies for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2019526622A JP2019526622A (ja) 2019-09-19
JP2019526622A5 JP2019526622A5 (enExample) 2020-09-17
JP7137563B2 true JP7137563B2 (ja) 2022-09-14

Family

ID=61073084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527783A Active JP7137563B2 (ja) 2016-08-05 2017-08-04 がん治療用の抗Ｓｉｇｌｅｃ－７抗体

Country Status (13)

Country Link
US (1) US11773162B2 (enExample)
EP (1) EP3494142A4 (enExample)
JP (1) JP7137563B2 (enExample)
KR (1) KR20190035863A (enExample)
CN (1) CN109790223A (enExample)
AU (1) AU2017307616A1 (enExample)
BR (1) BR112019002331A2 (enExample)
CA (1) CA3032437A1 (enExample)
EA (1) EA201990296A1 (enExample)
IL (1) IL264674B2 (enExample)
MX (1) MX2019001471A (enExample)
SG (1) SG11201901020RA (enExample)
WO (1) WO2018027203A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EA201990296A1 (ru) 2016-08-05 2019-08-30 Аллакос, Инк. Антитела против siglec-7 для лечения рака
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US11447545B2 (en) 2017-07-10 2022-09-20 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
AU2019208025A1 (en) * 2018-01-11 2020-09-03 Allakos, Inc. Anti-Siglec-7 antibodies having reduced effector function
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021247821A1 (en) * 2020-06-03 2021-12-09 The Wistar Institute Of Anatomy And Biology Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
JP2025027841A (ja) * 2023-08-17 2025-02-28 国立大学法人 東京大学 ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CA2691734A1 (en) * 2007-07-04 2009-01-08 Forerunner Pharma Research Co., Ltd. Anti-muc17 antibody
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP2999717B1 (en) * 2013-05-21 2018-08-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Treatment of mast cell related pathologies
CA2957502C (en) 2014-08-07 2021-07-20 Daiichi Sankyo Company, Limited Anti-orai1 antibody
EP3341411B1 (en) * 2015-08-28 2025-06-11 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
EP3402516A4 (en) 2016-01-12 2020-01-08 Palleon Pharmaceuticals Inc. USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
CN108699158B (zh) * 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
EA201990296A1 (ru) 2016-08-05 2019-08-30 Аллакос, Инк. Антитела против siglec-7 для лечения рака

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016038064A1 (en) 2014-09-10 2016-03-17 Innate Pharma Cross reactive siglec antibodies

Also Published As

Publication number Publication date
BR112019002331A2 (pt) 2019-06-18
MX2019001471A (es) 2019-10-30
IL264674B2 (en) 2023-09-01
EA201990296A1 (ru) 2019-08-30
EP3494142A1 (en) 2019-06-12
IL264674B1 (en) 2023-05-01
AU2017307616A1 (en) 2019-02-28
CA3032437A1 (en) 2018-02-08
EP3494142A4 (en) 2020-04-01
US20190194323A1 (en) 2019-06-27
CN109790223A (zh) 2019-05-21
KR20190035863A (ko) 2019-04-03
IL264674A (enExample) 2019-03-31
US11773162B2 (en) 2023-10-03
WO2018027203A1 (en) 2018-02-08
JP2019526622A (ja) 2019-09-19
SG11201901020RA (en) 2019-03-28

Similar Documents

Publication Publication Date Title
US11773162B2 (en) Anti-Siglec-7 antibodies for the treatment of cancer
JP7351845B2 (ja) Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CA3054824A1 (en) Anti-icos agonist antibodies and uses thereof
US20180134771A1 (en) Novel immunomodulatory therapeutic strategies targeting tumors in cancer
EP3955960A1 (en) Ipilimumab variants with enhanced specificity for binding at low ph
JP7342005B2 (ja) エフェクター機能が減少した抗ｓｉｇｌｅｃ－７抗体
JP7505148B2 (ja) Ｌａｇ３に結合する抗体およびその使用
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
AU2021308586A1 (en) Therapeutic antibodies and their uses
US20250042996A1 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
JP2025537137A (ja) 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
TW202523694A (zh) 抗muc16抗體及其用途
TW202446419A (zh) 使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法
HK1249409A1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220902

R150 Certificate of patent or registration of utility model

Ref document number: 7137563

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150